Comparative Pharmacology
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE 0 1 AND DEXTROSE 5 IN PLASTIC CONTAINER versus PEDIATRIC LTA KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE 0 1 AND DEXTROSE 5 IN PLASTIC CONTAINER versus PEDIATRIC LTA KIT.
LIDOCAINE HYDROCHLORIDE 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER vs PEDIATRIC LTA KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is a sodium channel blocker, which stabilizes neuronal membranes and inhibits the initiation and conduction of nerve impulses. Dextrose 5% provides caloric support.
PEDIATRIC LTA KIT contains lidocaine, tetracaine, and epinephrine. Lidocaine and tetracaine are amide and ester local anesthetics, respectively, that block voltage-gated sodium channels, preventing nerve impulse propagation. Epinephrine is a sympathomimetic that causes vasoconstriction, prolonging local anesthetic effect and reducing systemic absorption.
Intravenous: 50-100 mg bolus (1-2 mg/kg) over 2-3 minutes, followed by continuous infusion at 1-4 mg/min (20-50 mcg/kg/min). Total maximum dose: 300 mg over 1 hour.
Not applicable. Pediatric LTA Kit is a topical lidocaine/tetracaine patch for dermal anesthesia. Adult dose: apply one patch to intact skin for 20-30 minutes prior to procedure; remove prior to procedure. Maximum 3 patches per session. Not for systemic use.
None Documented
None Documented
Terminal elimination half-life: 1.5–2.0 hours in adults with normal hepatic function. In patients with hepatic impairment or heart failure, half-life may be prolonged (>3 hours). Clinical context: short half-life requires continuous infusion for sustained antiarrhythmic effect.
2-3 hours (terminal) in children with normal renal function; prolonged in renal impairment
Renal: approximately 10% unchanged; hepatic metabolism to 4-hydroxy-2,6-xylidine and glycylxylidide, which are excreted renally. Total renal excretion of metabolites and parent drug accounts for >95% of the dose. Fecal excretion is minimal (<5%).
Renal (95% as unchanged drug), fecal (5%)
Category A/B
Category C
Local Anesthetic / Antiarrhythmic (Class Ib)
Local Anesthetic